Trial Profile
A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECTS WITH TYPE II DIABETES MELLITUS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2012
Price :
$35
*
At a glance
- Drugs Indeglitazar (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Wyeth
- 08 Nov 2012 New source identified and integrated (EudraCT2005-004227-19: European Clinical Trials Database).
- 05 Nov 2010 New trial record.